Natixis Advisors LLC Boosts Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Natixis Advisors LLC raised its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 45,171 shares of the company’s stock after purchasing an additional 1,997 shares during the period. Natixis Advisors LLC owned 0.06% of IDEXX Laboratories worth $18,675,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the business. Atala Financial Inc purchased a new position in shares of IDEXX Laboratories in the fourth quarter worth about $102,000. Lazard Freres Gestion S.A.S. bought a new position in shares of IDEXX Laboratories in the fourth quarter valued at approximately $20,309,000. Skandinaviska Enskilda Banken AB publ boosted its position in shares of IDEXX Laboratories by 11.2% in the fourth quarter. Skandinaviska Enskilda Banken AB publ now owns 18,913 shares of the company’s stock valued at $7,806,000 after acquiring an additional 1,900 shares during the period. Erste Asset Management GmbH boosted its position in shares of IDEXX Laboratories by 17.9% in the fourth quarter. Erste Asset Management GmbH now owns 3,290 shares of the company’s stock valued at $1,365,000 after acquiring an additional 500 shares during the period. Finally, EverSource Wealth Advisors LLC boosted its position in shares of IDEXX Laboratories by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 453 shares of the company’s stock valued at $187,000 after acquiring an additional 201 shares during the period. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Trading Down 0.7 %

IDXX stock opened at $419.52 on Wednesday. The company has a market capitalization of $34.12 billion, a PE ratio of 39.32, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39. IDEXX Laboratories, Inc. has a one year low of $398.50 and a one year high of $548.88. The company’s 50 day moving average price is $437.74 and its two-hundred day moving average price is $445.87. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31.

Insiders Place Their Bets

In related news, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now directly owns 3,061 shares of the company’s stock, valued at $1,426,242.34. The trade was a 49.50 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the transaction, the executive vice president now directly owns 8,176 shares in the company, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 2.11% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on IDXX shares. Piper Sandler raised their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research report on Monday, February 10th. Leerink Partners started coverage on shares of IDEXX Laboratories in a research report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price objective for the company. Morgan Stanley cut their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a research report on Wednesday, January 29th. Leerink Partnrs upgraded shares of IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, Bank of America lifted their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a research report on Tuesday, February 4th. Four investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $533.75.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.